THSNA 2026 - Portland, OR

PROGRAM MENU

EDUCATIONAL PROGRAM

PRE-SUMMIT WORKSHOPS

Workshop Schedule

SATELLITE SYMPOSIA

Host a Satellite Symposium

Educational Program

THSNA programming is focused on presenting the most current issues in Hemostasis and Thrombosis. THSNA 2026 will include daily plenary sessions (without other concurrent sessions); four educational tracks, a Pre-Summit Workshop Day, daily ePoster sessions, oral abstract presentations of original research and an exhibit hall with commercial booths.

Wed - Mar 18

Thu - Mar 19

Fri - Mar 20

Sat - Mar 21

View Program Details

SATURDAY, MARCH 21

7:00 - 8:00 AM

SATELLITE SYMPOSIUM

DRIVING INNOVATION FORWARD IN HEMOPHILIA B WITH GENE THERAPY: CLINICAL CONVERSATIONS ON PROGRESS AND GUIDANCE ON PRACTICAL DELIVERY (PROVIDED BY PEERVIEW LIVE, SUPPORTED BY CSL BEHRING)
B113-114

To register and learn more, visit: PeerView. com/Portland26-Live For patients with hemophilia B who are accustomed to the demands of lifelong intravenous factor IX replacement therapy, advances with gene therapy represent a fundamental reimagining of what effective disease control could look like. However, numerous questions remain regarding the role of gene therapy within an expanding hemophilia treatment landscape and how to safely deliver care. Join PeerView for this CaseBook live symposium to hear our expert panel engage in dynamic case-based dialogue that illustrates the therapeutic impact of gene therapy in hemophilia B and offers care team clinicians strategies for implementing a collaborative, multimodal treatment model to overcome implementation barriers. Dont miss this opportunity to gain real-world insights on evidence-based, patient-centered approaches to gene therapy in hemophilia Bregister today to join us! Credits: CME: 1. 0 AMA PRA Category 1 CreditTM AAPA: 1 AAPA Category 1 CME credits IPCE: 1. 0 Interprofessional Continuing Education (IPCE) credit

7:00 - 1:00 PM

EVENT/OTHER

REGISTRATION
Oregon Ballroom Lobby

8:15 - 9:45 AM

HEMOSTASIS / BASIC SCIENCE

DIFFERENT PERSPECTIVES OF GENETICS IN HEMOSTASIS
Chair/Organizer: Dawn Rotellini, Jordan Shavit
Oregon Ballroom 201

8:15

GENE MODIFIERS OF BLEEDING DISORDERS USING ZEBRAFISH (BASIC/TRANSLATIONAL PERSPECTIVE)
JORDAN SHAVIT.

8:45

GENE MODIFIERS OF RARE BLEEDING DISORDERS (ATHN 10 STUDY, CLINICAL PERSPECTIVE)
DIANE NUGENT.

9:15

PATIENT ADVOCATE ON THE ROLE OF GENETIC TESTING IN THEIR DIAGNOSIS, TREATMENT, & QOL
SHELLYE HOROWITZ.

8:15 - 9:45 AM

LABORATORY

RARE BLEEDING DISORDERS
Chair/Organizer: Cathy Hayward, Bethany Samuelson Bannow
Oregon Ballroom 204

8:15

UTILITY AND COST-EFFECTIVENESS OF GENETIC TESTING IN DIAGNOSIS OF BLEEDING DISORDERS/BLEEDING OF UNKNOWN CAUSE
MEGAN CHAIGNEAU.

8:45

DIAGNOSING PLASMINOGEN DEFICIENCY - CLINICAL AND LABORATORY CONSIDERATIONS
AMY SHAPIRO.

9:15

PATIENT JOURNEYS TO DIAGNOSIS OF A RARE BLEEDING DISORDER
CAROLINE KRUSE.

8:15 - 9:45 AM

THROMBOSIS

THE CLOT THICKENS: NAVIGATING THROMBOSIS RISK IN CANCER PATIENTS
Chair/Organizer: Rushad Patell, Arthur Allen
Oregon Ballroom 203

8:15

ARTERIAL THROMBOSIS IN CANCER
A LEADER.

8:45

ANTICOAGULATING THE CANCER PATIENT WHO HIGHER RISK FOR BLEEDING (BRAIN TUMOR, METS, THROMBOCYTOPENIA)
KRISTEN SANFILLIPO.

9:15

THERAPEUTIC ADVANCES IN TREATING AND PREVENTING CA ASSOCIATED THROMBOSIS
MARC CARRIER.

9:45 - 10:30 AM

POSTERS/EXHIBITS/BREAK

POSTERS/EXHIBITS/BREAK (click to view) (click to close)
Exhibit Hall A

A3. VASCULAR WALL BIOLOGY, ENDOTHELIAL PROGENITOR CELLS AND PLATELET ADHESION

700

IMANIXIL-MEDIATED DISRUPTION OF LIPID TRAFFICKING IMPAIRS HEPATIC HEMOGLOBIN CLEARANCE IN SICKLE CELL DISEASE
AYYANAR SIVANANTHAM¹, NANDHINE RAJASEKAR², MARTA WOLOSOWICZ¹, NICHOLAS SWENDROWSKI¹, TIRTHADIPA PRADHAN-SUNDD^{2, 3}. ¹Thrombosis and Hemostasis Program, Versiti Blood Research Institute and Blood Center of Wisconsin, Milwaukee, WI, USA. ²Transfusion Medicine, Vascular Biology and Cell Therapy Program, Versiti Blood Research Institute, Milwaukee, WI, USA. ³Department of Cell Biology, Neurobiology and Anatomy, Medical college of Wisconsin, Milwaukee, WI, USA

A4. DISORDERS OF PLATELET NUMBER OR FUNCTION

701

EFFICACY AND SAFETY OF CAPLACIZUMAB IN THROMBOTIC THROMBOCYTOPENIC PURPURA: A SYSTEMATIC REVIEW AND META-ANALYSIS
URSULA MEDEIROS ARAUJO DE MATOS¹, PEDRO LUIZ LAGE BODOUR DANIELIAN², RITIKA VANKINA³. ¹Internal Medicine Department, University of Connecticut, Farmington, CT, USA. ²Harvard T. H. Chan School of Public Health, Boston, MA, USA. ³Hematology Oncology Department, University of Connecticut, Farmington, CT, USA

A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS

702

INNATE IMMUNE CELL ACTIVATION IS ASSOCIATED WITH ANAPHYLACTIC OUTCOMES IN FACTOR IX EXPOSED HEMOPHILIA B MICE
HUONG CHAU, ELIZABETH YORK, ATHENA S ARAGON, VERONICA GONZALEZ-PENA, CHARLES GAWAD, GLAIVY BATSULI. Stanford University, Palo Alto, CA, USA

703

DETERMINATION OF REGV131-LNP1265-DERIVED HUMAN FACTOR IX ACTIVITY USING ONE-STAGE CLOTTING AND CHROMOGENIC SUBSTRATE ASSAYS: RESULTS FROM A COMPARATIVE FIELD STUDY
KAROLINE A. MEAGHER¹, ROBERT J. DURSO¹, KEHDIH LAI¹, DAN CHALOTHORN¹, NATALIE NIEPOTH¹, SHANE MCCARTHY¹, SARA HAMON¹, DAVID E. GUTSTEIN¹, MEAGAN P. OA¹, STEFAN TIEFENBACHER², WILLIAM PICKERING², MARY ROBINSON³, MICHAEL E. BURCZYNSKI¹. ¹Regeneron Pharmaceuticals, Inc, Tarrytown, NJ, USA. ²Colorado Coagulation, Laboratory Corporation of America HoldingsAr, Englewood, CO, USA. ³Colorado Coagulation, Laboratory Corporation of America HoldingsAr (at the time of the study), Englewood, CO, USA

704

DETECTION OF CONTACT PATHWAY BIOMARKERS IN ECMO PATIENT PLASMA TO ASSESS DEVICE-ASSOCIATED THROMBOSIS
JENNY SI HAN WANG¹, ROSEMARY B. FALAMA², HELEN H. VU³, CRISTINA PUY¹, OWEN J. T. MCCARTY¹, JOSEPH J. SHATZEL^{1, 3, 4}. ¹Department of biomedical engineering, Portland, OR, USA. ²Department of medicine, Portland, OR, USA. ³Knight Cancer Institute, Portland, OR, USA. ⁴Division of Hematology and Medical Oncology, Portland, OR, USA

A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS

705

VENOUS THROMBOEMBOLISM AND BLEEDING IN ADVANCED MELANOMA: A PROPENSITY-MATCHED COHORT ANALYSIS COMPARING FIRST-LINE IMMUNOTHERAPY AND TARGETED THERAPY
FURKAN BAHAR¹, LAUREN OA², SORAVIS OSATAPHAN², REED DREWS², RUSHAD PATELL². ¹Department of Internal Medicine, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, USA. ²Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

706

OUTCOMES BY DOSE ESCALATION CRITERIA IN PARTICIPANTS WITH HEMOPHILIA A OR B WITHOUT INHIBITORS RECEIVING MARSTACIMAB IN THE BASIS TRIAL
LAURENT FRENZEL¹, TRAVIS GOULD², PENGLING SUN³, ANDREW PALLADINO⁴, OLIVER GLASS³. ¹Department of Haematology, Hemophilia Care and Research, Necker Hospital, Institut Imagine, Paris, France. ²Pfizer Inc, New York, NY, USA. ³Pfizer Inc, Cambridge, MA, USA. ⁴Pfizer Inc, Collegeville, PA, USA

707

SAFETY AND EFFICACY OF PDVWF/FVIII 1:1 PROPHYLAXIS IN CHILDREN UNDER 6 YEARS WITH SEVERE VWD: RESULTS FROM THE WIL-33 STUDY
AKSHAT JAIN¹, CINDY LEISSINGER², VLADIMIR VDOVIN³, PAVEL ZHARKOV⁴, LEONID DUBEY⁵, VALENTIN ACUREA⁶, ZORICA TRAJKOVA ANTEVSKA⁷, ESTER ZAPOTOCKA⁸, BOHUMASR BLAA&FRAC34;EK⁹, SUSAN HALIMEH¹⁰, AMANDA RODRIGUEZ¹¹, TARJA-ELINA WEISZ¹², CRISTINA SOLOMON¹³, ROBERT F. SIDONIO JR¹⁴. ¹Medical Director Hemophilia Treatment Center, Loma Linda University School of Medicine, Loma Linda, CA, USA. ²Tulane University, New Orleans, LA, USA. ³Morozovskaya Childrena, Moscow, Russia. ⁴Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia. ⁵Communal Institution of Lviv Regional Council, Western Ukrainian Specialized Childrena, Lviv, Ukrenia. ⁶IMSP Mother and Child Institute, ChiE, Moldova. ⁷ERASE Zorica Trajkova Antevska, PHI University Clinic for Child Diseases, Skopje, Moldova. ⁸Department of Pediatric Hematology and Oncology, University Hospital Motol and Second Faculty of Medicine, Charles University, Prague, Czech Republic. ⁹University Hospital Ostrava, Ostrava, Czech Republic. ¹⁰Gerinnungszentrum Rhein Ruhr, Duisburg, Germany. ¹¹Octapharma US, Paramus, NJ, USA. ¹²Octapharma Pharmazeutika Produktionsgesellschaft m. b. H, Vienna, Austria. ¹³Octapharma AG, Clinical Research and Development and Clinical Operations Haematology, Lachen, Switzerland. ¹⁴Professor of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA

708

EVALUATING PEN-INJECTOR HANDLING AND PROS IN PATIENTS SWITCHING FROM EMICIZUMAB TO MIM8 IN FRONTIER5
JOHNNY MAHLANGU¹, SANJAY AHUJA², ERIN COCKRELL³, VASCTOR JIMACNEZ-YUSTE⁴, MICHELE SCHIAVULLI⁵, AMALIE RHODE HACGH NIELSEN⁶, CAMILA MARTINS MAZINI TAVARES⁶, EMILY WATERS⁷, CACDRIC HERMANS⁸, DAN JOHNSON⁷. ¹Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. ²Indiana Hemophilia a Thrombosis Center, Innovative Hematology, Indianapolis, IN, USA. ³Pediatric Hematology Oncology, Saint Josepha, Tampa, FL, USA. ⁴Hematology Department, La Paz University Hospital, Hospital La Paz Institute for Health Research, Universidad AutA³noma Madrid, Madrid, Spain. ⁵Santobono-Pausilipon, Childrena, Naples, Italy. ⁶Novo Nordisk A/S, SAcborg, Denmark. ⁷Novo Nordisk Inc, Plainsboro, NJ, USA. ⁸Division of Hematology, Cliniques universitaires Saint-Luc, UniversitAc catholique de Louvain (UCLouvain), Brussels, Belgium

709

PERFORMANCE EVALUATION, PRECISION AND METHOD COMPARISON OF A NOVEL AUTOMATED COAGULATION ANALYZER
GABRIELLE PEARL, LISA MEADOWS, VICKIE SIMMONS, MARY KNIGHTEN, LASHANTA BRICE, PAUL RILEY. Diagnostica Stago, Inc, Parsippany, NJ, USA

710

RURIOCTOCOG ALFA PEGOL USE IN IMMUNE TOLERANCE INDUCTION: AN ANALYSIS OF A PHASE 3 STUDY IN PREVIOUSLY UNTREATED PATIENTS WITH SEVERE HEMOPHILIA A
ROBERT F. SIDONIO, JR. ¹, FLORA PEYVANDI^{2, 3}, RACHEL S. BERCOVITZ⁴, SEOH LENG YEOH⁵, ZULAIHA MUDA⁶, PHU QUOC LE⁷, VEERLE MONDELAERS⁸, JIAAN-DER WANG⁹, RASHID KAZMI¹⁰, BA&FRAC14;LENT ZA&FRAC14;LFIKAR¹¹, JOAN GU¹², SRILATHA TANGADA¹². ¹Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, GA, USA. ²Angelo Bianchi Bonomi Hemophilia and Thrombosis Centre, Fondazione IRCCS Caa, Milan, Italy. ³Department of Pathophysiology and Transplantation, UniversitAndegli Studi di Milano, Milan, Italy. ⁴Department of Pediatrics, Northwestern University Feinberg School of Medicine, and Division of Hematology, Oncology, Neuro-Oncology, and Stem Cell Transplant, Ann a Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA. ⁵Department of Pediatrics, Hospital Pulau Pinang, Penang, Malaysia. ⁶Paediatric Department, Hospital Tunku Azizah Women Children Hospital, Kuala Lumpur, Malaysia. ⁷HAcmato-Oncologie, HAapital Universitaire des Enfants Reine Fabiola, Brussels, Belgium. ⁸Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent University, Ghent, Belgium. ⁹Center for Rare Disease and Hemophilia, Taichung Veterans General Hospital, Taichung, Taiwan. ¹⁰University Hospital Southampton, Southampton, United Kingdom. ¹¹Department of Paediatric Haematology/Oncology, Istanbul University Oncology Institute, Istanbul, Turkey. ¹²Takeda Development Center Americas, Inc, Cambridge, MA, USA

711

PHARMACOKINETICS OF PLASMINOGEN, HUMAN-TVMH IN SUBJECTS WITH PLASMINOGEN DEFICIENCY TYPE 1
KAREN THIBAUDEAU¹, JOSEPH PARKER², PIERRE CHELLE³, ANDREA EDGINTON³, AMY SHAPIRO⁴. ¹Kedrion Biopharma Inc, Laval, QC, Canada. ²Kedrion Biopharma Inc, Fort Lee, NJ, USA. ³University of Waterloo, Waterloo, ON, Canada. ⁴Indiana Hemophilia a Thrombosis Center, Indianapolis, IN, USA

A7. PATHOPHYSIOLOGY OF THROMBOSIS

712

PROFILING OF EXTRACELLULAR VESICLES AND THROMBO-INFLAMMATORY BIOMARKERS IN PATIENTS WITH PULMONARY EMBOLISM
PRAKASHA KEMPAIAH¹, MIRA NIGUDKAR¹, MARTIN LUNDY¹, FAHIKA SIDDIQUI¹, CHONGYU ZHANG¹, BULENT KANTARCIOGLU¹, DEBRA HOPPENSTEADT¹, JEANINE WALENGA¹, THAO DOAN², JAWED FAREED¹, AMIR DARKI³, W. KEITH JONES ¹. ¹Loyola University Stritch School of Medicine, Chicago, IL, USA. ²AbbVie, North Chicago, Illinois, USA, Chicago, IL, USA. ³Division of Cardiovascular Disease and Department of Internal Medicine, Loyola University Chicago, Chicago, IL, USA

A8. ANTITHROMBOTIC THERAPY

713

MULTIMODAL DEEP LEARNING FOR PULMONARY EMBOLISM SCREENING USING CHEST X-RAY AND ELECTROCARDIOGRAM DATA
AWAN AFIAZ^{1, 2}, STEPHEN SALERNO², SOMIN M LEE³, ASHER MENDELSON⁴, BARRET RUSH⁵, MATTHEW SAMUEL⁵, MAX TANG⁶, TAKESHI TOHYAMA⁷, JENNIFER ZIEGLER⁸, LEO A CELI^{9, 10, 11}, JEFFREY T LEEK^{1, 2}, BARBARA LAM¹². ¹Department of Biostatistics, University of Washington, Seattle, WA, USA. ²Public Health Sciences, Biostatistics, Fred Hutchinson Cancer Center, Seattle, WA, USA. ³University of Toronto, Toronto, ON, Canada. ⁴Section of Critical Care, Department of Medicine, University of Manitoba, Winnipeg, MB, Canada. ⁵Massachusetts Institute of Technology, Cambridge, MA, USA. ⁶University of Waterloo, Waterloo, ON, Canada. ⁷Institute for Medical Engineering a Science, Massachusetts Institute of Technology, Cambridge, MA, USA. ⁸Department of Medicine, University of Manitoba, Winnipeg, MB, Canada. ⁹Laboratory for Computational Physiology, Massachusetts Institute of Technology, Cambridge, MA, USA. ¹⁰Division of Pulmonary, Critical Care and Sleep Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA. ¹¹Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA, USA. ¹²Division of Hematology/Oncology, Department of Medicine, Fred Hutchinson Cancer Center, Seattle, WA, USA

714

THE SENTINEL ROLE OF THE PATHOLOGIST IN DISTINGUISHING BIVALIRUDIN OVERDOSING FROM CONTAMINATION IN PEDIATRIC PATIENTS ON ECLS
VADIM KOSTOUSOV¹, KAREN BRUZDOSKI¹, JUN TERUYA^{1, 2, 3}. ¹Department of Pathology a Immunology, TCH, BCM, Houston, TX, USA. ²Department of Pediatrics, TCH, BCM, Houston, TX, USA. ³Department of Medicine, TCH, BCM, Houston, TX, USA

715

A SINGLE-CENTER ANALYSIS OF BIVALIRUDIN INFUSION RATES IN PEDIATRIC PATIENTS REQUIRING SYSTEMIC ANTICOAGULATION FOR TREATMENT OR PREVENTION OF THROMBOSIS.
JENNIFER PAK¹, KRISTIN MAHER², KIARA LIGHT¹, KARYL KANADA², NABIHA HUQ SAIFEE³, GAVIN ROACH². ¹Department of Pharmacy, Seattle Childrena, Seattle, WA, USA. ²Division of Hematology-Oncology, Seattle Childrena, Seattle, WA, USA. ³Department of Lab Medicine and Pathology, University of Washington, Seattle, WA, USA

A9. INFORMATIONAL ABSTRACT (POSTER ONLY)

716

OPTIMIZING TRANSCUTANEOUS AURICULAR NEUROSTIMULATION THERAPY FOR HEAVY MENSTRUAL BLEEDING: AN OPEN LABEL TRIAL
CHRISTOPHER J. CZURA¹, ANGELA C. WEYAND², MAUREEN K. BALDWIN³, MICHAEL RECHT^{4, 5}, CAROLINE BENNER¹, KIMIKO HARADA¹, BROOKE WADE¹, MEGHAN LUELLEN¹, MELANIE A. MCWADE¹, ALEJANDRO COVALIN¹, NAVID KHODAPARAST¹. ¹Spark Biomedical, Inc, Dallas, TX, USA. ²University of Michigan Medical School, Ann Arbor, MI, USA. ³Oregon Health Sciences University, Portland, OR, USA. ⁴Yale School of Medicine, New Haven, CT, USA

717

ANTICOAGULATION PRACTICES IN ANTIPHOSPHOLIPID SYNDROME: A RETROSPECTIVE CHART REVIEW
ANTHONY LIANG, ADAM CUKER, PARDIS NIAMI. Hospital of the University of Pennsylvania, Philadelphia, PA, USA

718

DEVELOPMENT OF A MULTIDISCIPLINARY PROGRAM FOR THE PREVENTION OF VENOUS THROMBOSIS IN AMBULATORY PATIENTS WITH CANCER
JOCELYN VEALS¹, KENDRA PRASAD¹, ANDREA CERVI^{1, 2}. ¹Schulich School of Medicine a Dentistry, London, ON, Canada. ²Department of Medical Oncology, Windsor Regional Cancer Center, Windsor, ON, Canada

10:30 - 11:30 AM

SHORT TALKS

SHORT TALKS - ADVANCES IN PLATELET DISORDERS: THERAPEUTICS, DIAGNOSTICS, AND CLINICAL MANAGEMENT
Chair/Organizer: Bethany Samuelson Bannow, Karen Flint
Oregon Ballroom 201

10:30

DISCREPANT RESULTS IN VON WILLEBRAND TESTING - AN ALGORITHMIC APPROACH TO ADDRESS HETEROPHILIC ANTIBODY INTERFERENCE IN THE INNOVANCEVWF GPIBM ACTIVITY ASSAY(THSNATRAVEL AWARDEE)
KAREN E. FLINT¹, JEREMY D. WILLIAMS¹, JOSHUA L. RHODES¹, KENNETH D. FRIEDMAN², ANDREA STAUM², SANDRA L. HABERICHTER², BAILEY HUTCHISON², ANDREW PODD², LORI LUCHTMAN-JONES^{1, 3}. ¹Hemostasis and Thrombosis Lab, Hematology Division, Cancer and Blood Diseases Institute, Cincinnati Childrena, Cincinnati, OH, USA. ²Diagnostic Laboratories, Versiti/Blood Center of Wisconsin, Milwaukee, WI, USA. ³Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA

10:42

UTILIZE SALINE CONTROL IN HEPARIN-INDUCED THROMBOCYTOPENIA FUNCTIONAL ASSAY TO IDENTIFY HEPARIN-INDEPENDENT ANTIBODIES (THSNATRAVEL AWARDEE)
JING JIN¹, KRINABEN PATEL¹, LU YANG², JAMES ZEHNDER². ¹Special Coagulation, Stanford Health Care Palo Alto, CA, USA. ²Department of Pathology, School of Medicine, Stanford University, Palo Alto, CA, USA

10:54

REDUCTION IN CONCOMITANT THERAPY USE WITH RILZABRUTINIB AND SUSTAINED RESPONSE IN ADULTS WITH PERSISTENT/CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) IN THE PHASE 3 LUNA3 LONG-TERM EXTENSION (LTE) PERIOD
DAVID J. KUTER¹, LEI ZHANG², WALEED GHANIMA³, YOSHITAKA MIYAKAWA⁴, YU HU⁵, DAVID GA&SUP3;MEZ-ALMAGUER⁶, MATIAS CORDOBA⁷, MAREK WARDA⁸, LARISSA MEGE⁹, MEREDITH C. FOSTER⁷, AHMED DAAK⁷, HOWARD A. LIEBMAN¹⁰, SANDHYA PANCH¹¹. ¹Hematology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. ²Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China. ³A, Oslo, Norway. ⁴Department of Hematology, Saitama Medical University, Saitama, Japan. ⁵Wuhan Xie'he Hospital, Wuhan, China. ⁶Hospital Universitario Dr. JosAc Eleuterio GonzAilez, Monterrey, Mexico. ⁷Sanofi, Cambridge, MA, USA. ⁸Sanofi, Warsaw, Poland. ⁹Sanofi, Lyon, France. ¹⁰University of Southern California, Los Angeles, CA, USA. ¹¹Fred Hutch, Fred Hutch, USA

11:06

THROMBOCYTOPENIA IN PREGNANCY: A 5-YEAR ANALYSIS OF CHARACTERISTICS AND PRACTICES FROM A SINGLE U. S. INSTITUTION
MACKENZIE LEMIEUX¹, MING LIM². ¹Division of Internal Medicine, University of Utah, Salt Lake City, UT, USA. ²2. Division of Hematology and Hematological Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA

11:18

RECOMBINANT VON WILLEBRAND FACTOR PROPHYLAXIS FOR SEVERE VON WILLEBRAND DISEASE: FINAL RESULTS FOCUSING ON ADULTS RECEIVING ONCE WEEKLY PROPHYLAXIS IN A PHASE 3B CONTINUATION STUDY
SOPHIE SUSEN¹, FRANK W G LEEBEEK², GIANCARLO CASTAMAN³, AMY L DUNN⁴, MARGARITA A TIMOFEEVA⁵, CAITLIN MONTCRIEFF⁶, MARIA WALIULLAH⁷, JINGMEI ZHANG⁷. ¹University of Lille, INSERM, CHU Lille, Institut Pasteur de Lille, Lille, France. ²Department of Hematology, Erasmus University Medical Center, Rotterdam, Netherlands. ³Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, Italy. ⁴Department of Hematology, Oncology, Bone Marrow Transplant and Apheresis, Nationwide Childrena, Columbus, OH, USA. ⁵Federal State Budgetary Scientific Institution, Kirov Scientific-Research Institute of Hematology and Blood Transfusion of Federal Medical and Biological Agency, Kirov, Russia. ⁶Takeda Pharmaceuticals U. S. A, Inc, Lexington, MA, USA. ⁷Takeda Development Center Americas, Inc, Cambridge, MA, USA

SHORT TALKS - COAGULATION SCIENCE AND VON WILLEBRAND FACTOR RESEARCH
Chair/Organizer: Samantha Carlson, Rebecca Risman
Oregon Ballroom 204

10:30

COMPARATIVE CLINICAL AND ECONOMIC EVALUATION OF ON-DEMAND VERSUS PROPHYLACTIC TREATMENT WITH PDVWF/FVIII 1:1 AND RECOMBINANT VWF IN ADULTS WITH TYPE 3 VON WILLEBRAND DISEASE IN THE UNITED STATES
ROBERT F SIDONIO JR¹, NATHAN T CONNELL^{2, 3, 4}, FERNANDO CORRALES-MEDINA⁵, CAROLINE MALCOLMSON⁶. ¹Emory University School of Medicine, Atlanta, GA, USA. ²Boston Bleeding Disorders Center, Boston, MA, USA. ³Brigham and Women's Hospital, Boston, MA, USA. ⁴Harvard Medical School, Boston, MA, USA. ⁵University of Miami-Miller School of Medicine, Miami, FL, USA. ⁶University of Toronto, Toronto, ON, USA

10:42

FACTOR VIII PROTEIN MODIFICATIONS INFLUENCE THE IMMUNE RECOGNITION OF FVIIIFC-VWF-XTEN IN HEMOPHILIA A PATIENT SAMPLES (THSNATRAVEL AWARDEE)
ANA L. ALTAMIRANDA, MENGJIE J. KONG, HUONG CHAU, MAY CHIEN, ELIZABETH S. YORK, GLAIVY BATSULI. Stanford University, Palo Alto, CA, USA

10:54

COMPREHENSIVE COAGULATION PROFILING VIA ICOAGLAB IN PATIENTS TREATED WITH IMPELLA PUMPS
DANIEL HOARE, ANIKET JOSHI, ELI FOSTER, NATHANIEL HAI, ZIQIAN ZENG, SEEMANTINI NADKARNI. Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

11:06

ACCELERATION OF INTERNAL LYSIS OF CONTRACTED CLOTS IS DRIVEN BY BUNDLING AND ALIGNMENT OF FIBRIN FIBERS (THSNATRAVEL AWARDEE)
REBECCA RISMAN^{1, 2}, EVA IUNGBLUDT², JOSHUA PACKER³, NATHAN HUDSON³, JOHN WEISEL¹, VALERIE TUTWILER². ¹University of Pennsylvania, Philadelphia, PA, USA. ²Rutgers University, New Brunswick, NJ, USA. ³Eastern Carolina University, Greenville, NC, USA

11:18

VWF ACTIVITY GPIBM ASSAY KIT EVALUATION
JULIE I. TANGE¹, DONG CHEN¹, RAJIV K. PRUTHI^{1, 2}, JULIANA PEREZ BOTERO¹. ¹Division of Hematopathology, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN, USA. ²Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA

SHORT TALKS - EMERGING THERAPEUTICS AND PROPHYLACTIC STRATEGIES IN COAGULATION DISORDER
Chair/Organizer: Rushad Patell, Gabe Fontaine
Oregon Ballroom 203

Not available for CE.

10:30

THE EFFECT OF FIBRINOGEN CONCENTRATE ON CLOT STRENGTH IN PATIENTS WITH CONGENITAL AND ACQUIRED FIBRINOGEN DEFICIENCY
SUCHITRA ACHARYA¹, TRUPTI MEHTA SHAH², CRISTINA SOLOMON³, SIGURD KNAUB³, CLAUDIA DJAMBAS KHAYAT⁴, ASHOK ROY⁵, FAHEEZ MOHAMED⁵, KEYVAN KARKOUTI⁶, JEANNIE CALLUM^{7, 8}, TOSHKO LISSITCHKOV⁹, FLORA PEYVANDI^{10, 11}. ¹Northwell Health, New Hyde Park, NY, USA. ²Octapharma USA, Paramus, NJ, USA. ³Octapharma AG, Lachen, Switzerland. ⁴Hospital HAatel Dieu de France, Saint Joseph University, Beirut, Lebanon. ⁵Peritoneal Malignancy Institute, Basingstoke, United Kingdom. ⁶University of Toronto, Toronto, ON, Canada. ⁷Queena, Kingston, ON, Canada. ⁸Kingston Health Sciences Centre, Kingston, ON, Canada. ⁹Specialized Hospital for Active Treatment (SHAT) a, Sofia, Bulgaria. ¹⁰Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. ¹¹UniversitAn degli Studi di Milano, Milan, Italy

10:42

SUBCUTANEOUS FOUR-WEEK DOSING OF THE NOVEL PROTEIN S ANTIBODY VGA039 DEMONSTRATES SAFETY AND CLINICALLY MEANINGFUL BLEED REDUCTION IN PATIENTS WITH VON WILLEBRAND DISEASE: PHASE 1/2 MULTI-DOSE STUDY RESULTS
NICOLETTA C. MACHIN¹, SHRINATH KSHIRSAGAR², ADAM GIERMASZ³, JOHNNY MAHLANGU⁴, GABRIELA YAMAGUTI-HAYAKAWA⁵, SAVITA RANGARAJAN⁶, GENEVIEVE MOYER⁷, CHRISTINE KEMPTON⁸, JANE MASON⁹, MICHELLE SHOLZBERG¹⁰, PAULA VILLAASA¹¹, SANDIP PANICKER¹², EILEEN K. SAWYER¹², GARY PATOU¹², BENJAMIN KIM¹², ALLISON P. WHEELER¹³. ¹Division of Classical Hematology, Department of Medicine, University of Pittsburgh and Hemophilia Center of Western Pennsylvania, Pittsburgh, PA, USA. ²Advanced Center for Oncology, Haematology a Rare Disorders, K. J. Somaiya Medical College a Research Center, Somaiya Ayurvihar, Mumbai, India. ³Division of Hematology/Oncology, Department of Medicine, University of California Davis, Sacramento, CA, USA. ⁴Haemophilia Comprehensive Care Centre, Charlotte Maxeke Johannesburg Hospital, University of the Witwatersrand, Johannesburg, South Africa. ⁵Hemocentro UNICAMP, University of Campinas, Campinas, Brazil. ⁶University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom. ⁷The University of Colorado Hemophilia and Thrombosis Center, Aurora, CO, USA. ⁸Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA. ⁹Queensland Haemophilia Centre, Department of Haematology and BMT, Royal Brisbane and Womena, Brisbane, Australia. ¹⁰Departments of Medicine, and Laboratory Medicine and Pathobiology, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada. ¹¹Hospital das ClAsnicas, University of SApo Paulo, SApo Paulo, Brazil. ¹²Star Therapeutics, Inc, South San Francisco, CA, USA. ¹³Washington Center for Bleeding Disorders and Divisions of Pediatric Hematology/Oncology and Hematology/Oncology, University of Washington, Seattle, WA, USA

10:54

NXT007 PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A WITH OR WITHOUT FVIII INHIBITORS: A GLOBAL PHASE I/II MULTIPLE-ASCENDING-DOSE STUDY
MARIA ELISA MANCUSO^{1, 2}, DAVIDE MATINO³, DAN HART⁴, FRANCISCO JOSAC LA&SUP3;PEZ-JAIME⁵, CHRISTOPHE SCHMITT⁶, SANJAY AHUJA⁷, GIULIANA VENTRIGLIA⁶, ANNA KIIALAINEN⁶, LAURA YOUNG⁸, OLIVIER CATALANI⁶, MARK BELLETRUTTI⁹, TOM CHU ¹⁰, JERZY WINDYGA¹¹, VASCTOR JIMACNEZ-YUSTE¹², MICHAELA LEHLE⁶, JANICE M. STABER¹³. ¹Humanitas University, Pieve Emanuele, Milan, Italy. ²Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. ³McMaster University, Hamilton, Ontario, Canada. ⁴Roche Products Ltd, Welwyn Garden City, United Kingdom. ⁵Hospital Universitario Regional de MAilaga, MAilaga, Spain. ⁶F. Hoffmann-La Roche Ltd, Basel, Switzerland. ⁷Indiana Hemophilia and Thrombosis Center, Indianapolis, IN, USA. ⁸Auckland City Hospital, Auckland, New Zealand. ⁹Department of Pediatrics, University of British Colombia, Vancouver, British Columbia, Canada. ¹⁰Genentech, Inc, South San Francisco, CA, USA. ¹¹Department of Hemostasis Disorders and Internal Medicine, Laboratory of Hemostasis and Metabolic Diseases, Institute of Hematology and Transfusion Medicine, Warsaw, Poland. ¹²La Paz University Hospital-IdiPAZ, AutA³noma University, Madrid, Spain. ¹³Stead Family Department of Pediatrics, Carver College of Medicine, University of Iowa, Iowa City, IA, USA

11:06

EXPLORATORY ANALYSIS OF INTRINSIC PATHWAY-TRIGGERED THROMBIN GENERATION INHIBITION IN HEALTHY VOLUNTEERS AND PATIENTS POST-TOTAL KNEE ARTHROPLASTY WHO RECEIVED REGN9933A2 AND REGN7508CAT
KAROLINE A. MEAGHER, KUSHA MOHAMMADI, DATENG LI, ETHAN MARIN, AARON KITHCART, MEAGAN P. OA, SELIN SOMERSAN-KARAKAYA, KEHDIH LAI, DAN CHALOTHORN, ROBERT J. DURSO, MICHAEL E. BURCZYNSKI, POULABI BANERJEE, DAVID E. GUTSTEIN. Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA

11:18

FIRST-IN-HUMAN INVESTIGATION OF HMB-002: A SUBCUTANEOUS ANTIBODY FOR PROPHYLACTIC MANAGEMENT OF VON WILLEBRAND DISEASE
PRIYANKA RAHEJA¹, AMY KNOTT², ULRIKE LORCH³, HENRIK OSTERGAARD⁴, CATHERINE REA⁴. ¹Department of Hematology, The Royal London Hospital, Barts Health NHS Trust, London, United Kingdom. ²Bristol Haematology Unit, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom. ³Richmond Pharmacology, London, United Kingdom. ⁴Hemab Therapeutics, Cambridge, MA, USA

11:45 - 1:00 PM

PLENARY SESSION

THE ROLE OF ADVOCACY ORGANIZATIONS IN DRUG DEVELOPMENT, CT DESIGN, AND ADOPTION OF NEW KNOWLEDGE
Chair/Organizer: Anne Rose, Lana Castellucci
Oregon Ballroom 201

11:45

PATIENT ADVOCATE - NBDF
SAMANTHA CARLSON.

12:10

PATIENT ADVOCATE - PDSA
CAROLINE KRUSE.

12:35

CLINICIAN ADVOCATE
ROBERT SIDONIO.